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Abstract: 3,5-Disubstituted hydantoin (1,3-imidazolidinedione) derivatives 5a-h were 
prepared by base induced cyclization of the corresponding N-(1-benzotriazolecarbonyl)-L- 
and D-amino acid amides 4a-h. Compounds 5a-h were evaluated for their cytostatic and 
antiviral activities. Among all the compounds evaluated, 3-benzhydryl-5-isopropyl 
hydantoin (5a) showed a weak but selective inhibitory effect against vaccinia virus (EC50 = 
16 µg/mL; selectivity index: 25). 3-Cyclohexyl-5-phenyl hydantoin (5g) showed inhibitory 
activity against cervical carcinoma (HeLa, IC50 = 5.4 µM) and breast carcinoma (MCF-7, 
IC50 = 2 µM), but also cytotoxic effects towards human normal fibroblasts (WI 38). On the 
contrary, the 3-benzhydryl-5-phenyl substituted hydantoin derivative 5h showed moderate 
inhibitory activity towards HeLa, MCF-7, pancreatic carcinoma (MiaPaCa-2), lung 
carcinoma (H 460) and colon carcinoma (SW 620) (IC50 = 20−23 µM), but no effect on WI 
38. 
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Introduction 
 
Hydantoin (1,3-imidazolidinedione) derivatives display diverse and interesting pharmacological 
properties. Several such derivatives (phenytoin, mephenythoin, norantoin, methetoin, ethotoin, 
fosphenytoin) are well-known anticonvulsive drugs [1,2]. Other 5-substituted hydantoins like 5,5-
dithienylhydantoin, 5,5-dipyridylhydantoin, spirothiohydantoin, thiohydantoin and dithiohydantoins 
also possess anticonvulsive activity [3]. Hydantoin derivatives can also be found as antiarrhythmics 
(azimilide), antimicrobial agents (nitrofurantoin), skeletal muscle relaxants (dantrolene) and 
nonsteroidal antiandrogens (nilutamide), while allantoin is used as a keratolytic, astringent, wound 
remedy, antacid and antipsoriatic drug [2]. Hydantoins also exhibit antidepressant, antiviral and 
antithrombotic activities, as well as inhibitory activity against some enzymes (human aldose reductase 
and human leucocyte elastase) [4]. Finally, some herbicides (spirohydantoin, thioxohydantocidin), 
fungicides (clodantoin) and insecticides also have the hydantoin skeleton in their structure [5,6]. 
During our previous research a series of hydantoins were synthesized and evaluated for their antiviral 
and cytostatic activities [7,8]. The best pharmacological activities were achieved with lipophilic 
hydantoin derivatives bearing cycloalkyl, phenyl or benzhydryl substituents. This led us to prepare and 
pharmacologically evaluate a series of the novel structural analogues of these lead compounds in order 
to assess their antiviral and antitumoral potential. The results are reported in this paper. 
 
Results and Discussion 
 
Chemistry 
 
A series of 3,5-disubstituted hydantoins 5a-h were prepared by intramolecular cyclization of N-[(1-
benzotriazolecarbonyl (Btc)]-amino acid amides 4a-h, following our previously described procedures 
[7−9] (Scheme 1). All these hydantoins are new compounds, except 5d and 5g, whose syntheses have 
been previously described [9−11], although their cytostatic and antiviral activities have not been 
reported until now. Synthesis of the N-Btc-amino acid amides 4a-h and their precursors N-Btc-amino 
acid derivatives 2a-d and the corresponding chloride derivatives 3a-d were also described in our 
previous reports [12]. Syntheses of the compounds 4a-h and 5a-h were carried out under mild reaction 
conditions and the products were obtained in high yields. In the preparation of the amides 4a-h, an 
equimolar ratio of the N-Btc-amino acid chloride derivatives 3a-d and the corresponding amine was 
crucial in order to avoid formation of ureido amides. Our previous research results had shown that 3-
cyclohexanemethyl-5-phenylhydantoin possessed marked antiviral activity (i.e. against cytomegalo-
virus) [7]. Based on that lead compound we have now prepared some novel hydantoins containing one 
or two lipophilic substituents at positions 3 and 5. Three amino acids of the L-series (L-valine, L-
leucine and L-phenylalanine) and one D-amino acid (D-phenylglycine) and highly lipophilic amines 
(cyclopentyl-, cyclohexyl-, cyclohexanemethyl- or benzhydrylamines) were used as the starting 
reagents. As the chiral centre was not involved in chemical transformations of the L- and D-amino acid 
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precursors (Scheme 1) these configurations should be retained in the target hydantoin molecules [7]. 
The validity of this assumption has been proven by X-ray crystallographic analysis of the 
stereostructure of the hydantoin derivative of L-valine [8]. 
Scheme 1. Synthesis of hydantoin derivatives of L- and D-amino acids, 5a-f and 5g,h, respectively 
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Reagents and conditions: (i) anhydrous dioxane, rt, 24 h; (ii) SOCl2, rt, 24 h or reflux, 1 h; (iii) 
amine, Et3N, anhydrous toluene, rt, 24 h; (iv) Na2CO3, acetone, rt, 2 h. 
 
The structures of the newly synthesized compounds were deduced from the analysis of their 1H- 
and 13C-NMR and IR spectra, and confirmed by elemental analysis. The IR spectra of the hydantoin 
derivatives (Table 1) showed characteristic bands at 3421−3227 (NH), 1775−1760 and 1718−1698 
(CO) cm-1. The chemical shifts in 1H- and 13C-NMR spectra (Tables 2 and 3) are in concordance with 
the proposed structures of the novel compounds and also consistent with previously described 
analogous hydantoin derivatives [7]. 
 
Table 1. Analytical data of the novel N-Btc-L-valine benzhydrylamide (4a) and 3,5-
disubstituted hydantoin derivatives 5a-h. 
HN NR'
O
OR
H
5a-h
H
N
O
NHBtcH
CHPh2
4a  
Compd. R R' 
Yield 
(%) 
mp 
(°C) 
Molecular 
formula (Mr) 
IR (KBr) νmax (cm-1) 
4a − − 48 155−160 C25H25N5O2 
(427.25) 
3287, 2966, 1713, 1650, 
1556, 1524 
5a  
 
86 oil 
C19H20N2O2 
(308.37) 
3249, 3063, 3030, 2963, 
2930, 1772, 1711, 1417 
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Table 1. Cont. 
Compd. R R' 
Yield 
(%) 
mp 
(°C) 
Molecular 
formula (Mr) 
IR (KBr) νmax (cm-1) 
5b  
 
88 139−141 
C20H22N2O2 
(322.40) 
3421, 3265, 3110, 2956, 
1773, 1711, 1422 
5c   73 121−124 
C15H18N2O2 
(258.32) 
3258, 3091, 2959, 2868, 
1760, 1718, 1431 
5d   85 119−120 
C16H20N2O2 
(272.34) 
3270, 3093, 2926, 2856, 
1768, 1707, 1436 
5e   80 150−153 
C17H22N2O2 
(286.37) 
314, 3030, 2924, 2852, 
1768, 1698, 1454, 1428 
5f  
 
29 76 (decomp.) 
C23H22N2O2 
(356.42) 
3269, 3029, 2924, 1774, 
1711, 1419 
5g   37 180−184 
C15H18N2O2 
(258.32) 
3227, 3098, 3037, 2927, 
2856, 1765, 1705, 1429 
5h  
 
24 172−177 
C22H18N2O2 
(342.39) 
3230, 3093, 2825, 1774, 
1712, 1454, 1423 
 
Table 2. 1H-NMR spectral data of the novel N-Btc-L-valine benzhydrylamide (4a) and 
3,5-disubstituted hydantoin derivatives 5a-h. 
NHR'
O
NHRH
5
6
7
2 1''
3
4a
HN NR'
O
OR
H
5a-h
1 3
5
 
Compd.   R R' 1H-NMR (DMSO-d6) δ ppm 
4a 
N
N N
O 2'
3'
5'
4
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
9.19 (d, 1H, 3, J = 8.4 Hz), 8.68 (d, 1H, 1'', J = 8.5 Hz), 8.25−7.14 (m, 14H, 
arom.), 6.20 (d, 1H, 2'', J = 8.5 Hz), 4.49 (d, 1H, 2, J = 7.9 Hz), 2.34−2.23 
(m, 1H, 5), 0.96−0.70 (m, 6H, 6, 7) 
5a 
6
8
7
 
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
8.40 (s, 1H, 1), 7.38−7.23 (m, 10H, arom.), 6.35 (s, 1H, 2''), 4.07−4,06 (d, 
1H, 5, J = 3.3 Hz), 2,08−1,97 (m, 1H, 6, J = 3.4 Hz), 0.93−0.91 (d, 3H, 7,
J = 6.9 Hz), 0.72−0.70 (d, 3H, 8, J = 6.8 Hz) 
5b 
67
9
8
 
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
8.51 (s, 1H, 1), 7.38−7.22 (m, 10H, arom.), 6.34 (s, 1H, 2''), 4.20−4.16 (q, 
1H, 5, J = 4.1 Hz), 1.79−1.74 (m, 1H, 7, J = 4.7 Hz), 1.56−1.36 (m, 2H, 6,
J = 4.7 Hz), 0.88−0.85 (2d, 6H, 8, 9, J = 4.1 Hz) 
5c 89
10
11 12
7 6
 
3''
4''
5''
6''
2''
 
8.18 (s, 1H, 1), 7.28−7.13 (m, 5H, arom.), 4.30−4.27 (t, 1H, 5, J = 4.4 Hz), 
4.09−4.02 (m, 1H, 2'', J = 7.7 Hz), 2.94−2.93 (d, 2H, 6, J = 4.2 Hz), 
1.67−1.42 (m, 8H, 3''−6'') 
5d 89
10
11 12
7 6
 
2''
3'' 4''
5''
6''7''  
8.15 (s, 1H, 1), 7.28−7.13 (m, 5H, arom.), 4.30−4.27 (t, 1H, 5, J = 4.4 Hz), 
3.52−3.44 (m, 1H, 2'', J = 3.5 Hz), 2.94−2.92 (t, 2H, 6, J = 3.5 Hz), 
1.85−0.94 (m, 10H, 3''−7'') 
5e 
89
10
11 12
7 6
 
2'' 3''
5''
6''
7''8''
4''
 
8.21 (s, 1H, 1), 7.27−7.14 (m, 5H, arom.), 4.39−4.36 (t, 1H, 5, J = 4.2 Hz), 
3.05−2.87 (m, 4H, 6, 2''), 1.61−0.50 (m, 11H, 3''−8'') 
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Table 2. Cont. 
Compd.   R R' 1H-NMR (DMSO-d6) δ ppm 
5f 
89
10
11 12
7 6
 
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
8.44 (s, 1H, 1), 7.30−6.73 (m, 15H, arom.), 6.13 (s, 1H, 2''), 4.53−4.50 (t, 1H, 
5, J = 4.3 Hz), 3.07−2.94 (m, 2H, 6) 
5g 6
78
9
10 11  
2''
3'' 4''
5''
6''7''  
8.64 (s, 1H, 1), 7.44−7.29 (m, 5H, arom.), 5.13 (s, 1H, 5), 3.81−3.70 (m, 1H, 
2'', J = 3.8 Hz), 2.12−1,02 (m, 10H, 3''−7'') 
5h 6
78
9
10 11  
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
 
8.91 (s, 1H, 1), 7.43−7.20 (m, 15H, arom.), 6.39 (s, 1H, 2''), 5.34 (s, 1H, 5) 
 
Table 3. 13C-NMR spectral data of the novel N-Btc-L-valine benzhydrylamide (4a) and 
3,5-disubstituted hydantoin derivatives 5a-h. 
NHR'
O
NHRH
5
6
7
2 1''
4a
HN NR'
O
R
H
5a-h
1 3
5
1
2
4 O
 
Compd. R R' 13C-NMR (DMSO-d6) δ ppm 
 
4a 
N
N N
O 2'
3'
5'
4'
1'
6'
4
 
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
169.29 (1), 148.59 (4), 145.45 (1'), 142.00 (3'', 9''), 131.17 (6'), 
130.08 (5'), 128.30 (5'', 7'', 11'', 13''), 128.15 (4'', 8''), 127.24 (10'', 
14''), 127.15 (6''), 126.99 (12''), 125.61 (4'), 119.82 (3'), 113.37 
(2'), 63.90 (2), 56.04 (2'') 30.77 (5), 19.17 (6), 18.20 (7) 
 
5a 
 
6
8
7
 
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
173.63 (4), 156.87 (2), 138.63 (3''), 138.37 (9''), 128.56(4'', 8''), 
128.37 (5'', 7''), 128.32 (10'', 14''), 128.22 (11'',13''), 127.64 (6''), 
127.53''), 61.06 (2''), 57.14 (5), 29.92 (6), 18.64 (7), 15.84 (8) 
 
5b 
 
67
9
8
 
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
174.34 (4), 156.22 (2), 138.30 (3''), 138.21 (9''), 128.15 (4'', 8'', 
10'', 14''), 128.12 (5'', 7'', 11'', 13''), 127.33 (6'', 12''), 56.85 (2''), 
54.44 (5), 40.75 (6), 23.96 (7), 22.98 (8), 21.27 (9) 
 
5c 
 
89
10
11 12
7 6
 
 
3''
4''
5''
6''
2''
 
175.20 (4), 158.25 (2), 136.80 (7), 131.64 (8, 12), 129.81 (9, 11), 
128.55 (10), 58.11 (5), 51.90 (2''), 38.30 (6), 30.30 (6''), 30.02 
(3''), 26.39 (4'', 5'') 
5d 
89
10
11 12
7 6
 
2''
3'' 4''
5''
6''7''  
173.20 (4), 156.22 (2), 134.78 (7), 129.76 (8, 12), 127.82 (9, 11), 
126.60 (10), 56.04 (5), 49.64 (2''), 36.28 (6), 28.58 (3''), 28.39 
(7''), 25.18 (4'', 6''), 24.68 (5'') 
 
5e 
89
10
11 12
7 6
 
2'' 3''
5''
6''
7''8''
4''
 
173.27 (4), 156.60 (2), 134.78 (7), 129.80 (8, 12), 127.82 (9, 11), 
126.58 (10), 56.71 (5), 43.37 (2''), 35.95 (6), 35.66 (3''), 29.79 
(4''), 29.52 (8''), 25.65 (5''), 25.17 (7''), 25.12 (6'') 
 
5f 
89
10
11 12
7 6
 
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
172.87 (4), 155.72 (2), 138.01 (3''), 137.95 (9''), 134.65 (7), 
126.78−130.01 (8−12, 4''−8'', 10''−14'') 56.62 (5, 2''), 35.78 (6) 
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Table 3. Cont. 
Compd. R R' 13C-NMR (DMSO-d6) δ ppm 
 
5g 
6
78
9
10 11  
2''
3'' 4''
5''
6''7''  
172.36 (4), 156.61 (2), 135.91 (6), 128.62 (7, 11), 128.23 (8, 10), 
126.68 (9), 59.08 (5), 50.22 (2''), 28.92(3''), 28.83 (7''), 25.27 (4''), 
25.24 (6''), 24.72 (5'') 
 
5h 
6
78
9
10 11  
2'' 3''
4'' 5''
6''
7''8''9''
10''
11''
12''
13''
14''
 
172.35 (4), 156.54 (2), 138.96 (3''), 138.30 (9''), 135.85 (6), 
128.94−126.87 (7−11, 4''−8'', 10''−14''), 59.66 (2''), 57.35 (5) 
 
Biological Results 
 
The activities of the novel 3,5-disubstituted hydantoins 5a-h were evaluated against herpes simplex 
virus-1 (HSV-1 KOS strain ), herpes simplex virus-2 (HSV-2 strain G), herpes simplex virus-1 (ACV-
resistant KOS strain), vaccinia virus, vesicular stomatitis virus, Coxsackie virus B4, respiratory 
syncytial virus, parainfluenza-3 virus, reovirus-1, Sindbis virus and Punta Toro virus. These activities 
were compared with those of acyclovir, ganciclovir and ribavirin (Table 4). 
Table 4. Antiviral activity of the novel 3,5-disubstituted hydantoins 5a-h. 
EC50b 
Compd. 
MCC
a  1c 2 3 4 5 6 7 8 9 10 11 
5a 400 > 80 80 80 16 80 > 80 > 80 > 80 > 80 48 > 80 
5b 80 > 16 > 16 > 16 > 16 > 16 > 16 > 16 > 16 > 16 16 > 16 
5c > 400 > 400 240 > 80 240 > 400 240 > 400 > 400 > 400 240 > 400 
5d 80 > 16 > 16 > 16 > 16 > 80 80 > 80 > 80 > 80 > 80 > 80 
5e 400 > 80 > 80 > 80 > 80 > 16 > 16 > 16 > 16 > 16 > 16 > 16 
5f 80 > 16 > 16 > 16 16 > 16 16 > 16 16 16 16 > 16 
5g 80 > 16 > 16 > 16 > 16 > 80 > 80 > 80 > 80 > 80 > 80 > 80 
5h 80 > 16 > 16 > 16 > 16 > 16 16 > 16 16 16 16 > 16 
acyclovir > 100 0.11 0.18 13.51 67.5 > 100 ndd nd nd nd nd nd 
ganciclovir > 25 0.02 0.02 0.2 15.3 > 25 nd nd nd nd nd nd 
ribavirin > 100 > 100 73.3 > 100 24.4 > 100 > 100 > 100 73.3 73.3 24.4 73.3 
a MCC – minimum cytotoxic concentration (µg mL−1) that causes a microscopically detectable alternation 
of cell morphology; b EC50 – effective concentration (µg mL−1) required to reduce virus plaque formation 
by 50%. Virus input was 100 plaque forming units (PFU); c Viruses: 1 – HSV-1 (KOS), 2 – HSV-2 (G), 3 – 
HSV-1 TK KOS ACVr, 4 – Vaccinia virus, 5 – Vesicular stomatitis virus, 6 – Coxsackie virus B4, 7 – 
Respiratory syncytial virus, 8 – Parainfluenza-3 virus, 9 – Reovirus-1, 10 – Sindbis virus, 11 – Punta Toro 
virus; d Not determined. 
 
Structurally related hydantoin derivatives 5f and 5h exhibited similar inhibitory effects against the 
evaluated viruses. Thus, these compounds showed some antiviral activity against Coxsackie virus, 
parainfluenza-3 virus, reovirus-1 and Sindbis virus (EC50 = 16 µg mL−1); which is 5-fold lower than 
the minimum cytotoxic concentration (MCC). 3-Benzhydryl-5-isopropyl hydantoin (5a) showed 
inhibitory effects against vaccinia virus (EC50 = 16 µg mL−1), at 25-fold lower concentration than the 
MCC. 
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Compound 5f 
-100
-50
0
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log10 concentration (M)
P
G
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)
WI 38
HeLa
SW 620
H 460
MCF-7
MiaPaCa-2
The 3,5-disubstituted hydantoin derivatives 5a-h were also evaluated for their activities against 
malignant tumor cell lines: murine leukemia (L1210) and human T-lymphocytes (Molt4/C8 and 
CEM), cervical carcinoma (HeLa), breast carcinoma (MCF-7), pancreatic carcinoma (MiaPaCa-2), 
lung carcinoma (H 460), colon carcinoma (SW 620), as well as normal fibroblasts (WI 38) (Table 5). 
Table 5. Inhibitory effects of the novel 3,5-disubstituted hydantoins 5a-h on the growth 
of human malignant tumor cell lines and normal diploid fibroblasts (WI 38). 
Tumor cell growth a   
Compds 
1b 2 3 4 5 6 7 8 9 
5a 102 ± 3 183 ± 38 83 ± 4 > 100 36 ± 13 47 ± 5 65 ± 35 62 ± 20 77 ± 23 
5b 57 ± 21 232±194 148 ± 95 47 ± 44 16 ± 0.6 46 ± 29 43 ± 1.5 31 ± 27 42 ± 2 
5c > 500 > 500 406 ± 16 > 100 63 ± 14 > 100 > 100 > 100 > 100 
5d 303 ± 9 317 ± 12 266 ± 15 37 ± 141 18 ± 1 81 ± 10 > 100 78 ± 21 55 ± 14 
5e 312±128 > 500 246 ± 85 38 ± 8 22 ± 2 70 ± 19 > 100 74 ± 25 42 ± 2 
5f 42 ± 2 53 ± 2 48 ± 4 13 ± 1.4 11 ± 1 14 ± 0.9 19 ± 4 15 ± 2 13 ± 5 
5g 172 ± 52 277 ± 45 146 ± 14 5.4 ± 13 2 ± 1.6 58 ± 42 58 ± 25 60 ± 35 1.5 ± 0.3 
5h 46 ± 4 52 ± 5 50 ± 4 21 ± 3 20 ± 10 22 ± 0.7 23 ± 0.7 21 ± 0.9 > 100 
HU ndc nd nd 42 ± 38 > 100 > 100 > 100 > 100 > 100 
5-FU nd nd nd 4 ± 1.5 15 ± 2 10 ± 3 2 ± 0.7 9 ± 2 14 ± 12 
Cis nd nd nd 4 ± 3 12 ± 6 5 ± 1 0.3 ± 0.1 8 ± 6 20 ± 19 
a IC50 – 50% inhibitory concentration or compound concentration (µM) required to inhibit tumor cell 
proliferation by 50%; b Tumor cells: 1 – L1210, 2 – MoltC4/C8, 3 – CEM, 4 – HeLa, 5 – MCF-7, 6 – 
MiaPaCa-2, 7 – H 460, 8 – SW 620, 9 – normal diploid fibroblasts WI 38; c Not determined; HU – 
hydroxyurea, 5-FU – 5-fluorouracil, Cis – cisplatin. 
Amongst all evaluated compounds, 3-cyclohexyl-5-phenyl hydantoin (5g) showed rather marked 
inhibitory activity against HeLa (IC50 = 5.4 µM) and MCF-7 (IC50 = 2 µM) cell lines, but also high 
inhibitory effects on normal fibroblasts WI 38 (Figure 1).  
Figure 1. Dose-response profile for compounds 5f, 5g and 5h tested in vitro on various 
human cell lines *.  
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Figure 1. Cont. 
Compound 5g
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Compound 5h
-100
-50
0
50
100
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log10 concentration (M)
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G
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WI 38
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SW 620
H 460
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* The cells were treated with the compounds 5f-h at different concentrations, and percentage of 
growth (PG) was calculated. Each point represents the mean value of four parallel samples in 
three individual experiments. 
Similarly, 3-benzhydryl-5-benzyl hydantoin (5f) showed moderate inhibitory activity against all 
human tumor cell lines examined and also normal fibroblasts (WI 38). By contrast, the 3-benzhydryl-
5-phenyl substituted hydantoin derivative 5h showed a rather marked inhibitory activity against HeLa 
(IC50 = 21 µM), MCF-7 (IC50 = 20 µM), MiaPaCa-2 (IC50 = 22 µM), H 460 (IC50 = 23 µM) and SW 
620 (IC50 = 21 µM), and no cytotoxic effect on WI 38 fibroblasts. 
 
Conclusions 
 
In summary, the hydantoin derivatives presented herein showed certain antiviral and antitumor 
activity. Derivatives 5f and 5h exhibited weak inhibitory effects against the evaluated viruses and 
hydantoin 5a showed a weak but selective inhibitory effect against vaccinia virus. With regards to their 
antitumor activity, hydantoin 5g showed rather marked inhibitory activity against HeLa and MCF-7 
cell lines, while 5h showed inhibitory activity towards several tumor cell lines and no cytotoxic effects 
on normal cells. Further optimization of the hydantoin derivatives as potential antiviral and cytostatic 
agents is in progress. 
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Experimental  
 
General  
 
Melting points were determined on a Boëtius Micro Heating Stage and are uncorrected. IR spectra 
were recorded on a FTIR Perkin Elmer Paragon 500 spectrometer. 1H- and 13C-NMR spectra were 
recorded on a Varian Gemini 300 spectrometer, operating at 300 and 75.5 MHz for the 1H- and 13C- 
nuclei, respectively. Samples were measured in DMSO-d6 solutions at 20 ºC in 5 mm NMR tubes. 
Chemical shifts (δ) in ppm were referred to TMS. Precoated silica gel 60 F254 plates (Merck) were 
used for thin-layer chromatography, with 1:1 cyclohexane/ethyl acetate as the eluent. Spots were 
visualized by short-wave UV light and iodine vapour. 
 
Chemistry  
 
N-Btc-amino acid amides 4a-h  
 
The starting compounds for the hydantoin preparations, namely N-Btc-L-leucine benzhydrylamide 
(4b), N-Btc-L-phenylalanine cyclopentylamide (4c), N-Btc-L-phenylalanine cyclohexylamide (4d), N-
Btc-L-phenylalanine cyclohexanemethylamide (4e), N-Btc-L-phenylalanine benzhydrylamide (4f), N-
Btc-D-phenylglycine cyclohexylamide (4g), N-Btc-D-phenylglycine benzhydrylamide (4h) were 
prepared by procedures described previously [7,9], whereas the analogous L-valine benzhydrylamide 
(4a) is a new compound. 
 
N-Btc-L-valine benzhydrylamide (4a). To a cold solution of N-Btc-L-valine chloride 3a [9] (1.122 g, 4 
mmol) in toluene (40 mL), a solution of benzhydrylamine (0.732 g, 4 mmol) and triethylamine (0.404 
g, 4 mmol) in toluene (30 mL) was added dropwise. The reaction mixture was stirred at room 
temperature for 24 h. Product 4a, which precipitated together with TEA·HCl, was filtered off and 
dissolved in a dichloromethane/water mixture. The organic layers were extracted with diluted 
hydrochloride acid (w = 1%) and water, dried over sodium sulfate and evaporated in vacuo. The 
residue was triturated with ether to give the analytically pure 4a. The analytical, 1H- and 13C-NMR 
spectral data for 4a are given in Tables 1−3. 
 
General method for the synthesis of 3,5-disubstituted hydantoins 5a-h  
 
To a solution of N-(1-benzotriazolecarbonyl)-amino acid derivatives 4a-h (1.5 mmol) in acetone 
(60 mL), 5% sodium carbonate solution (5 mL) was added. The reaction mixture was stirred 2 h at 
room temperature. Acetone was evaporated in vacuo and the precipitated products 5a-h were filtered 
off, washed with water and recrystallized from acetone and water. The following hydantoins were 
prepared in this fashion: 3-benzhydryl-5-isopropyl hydantoin (5a), 3-benzhydryl-5-isobutyl hydantoin 
(5b), 3-cyclopentyl-5-benzyl hydantoin (5c), 3-cyclohexyl-5-benzyl hydantoin (5d), 3-cyclohexane-
methyl-5-benzyl hydantoin (5e), 3-benzhydryl-5-benzyl hydantoin (5f), 3-cyclohexyl-5-phenyl 
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hydantoin (5g) and 3-benzhydryl-5-phenyl hydantoin (5h). Their analytical data and yields are 
presented in Table 1, while 1H- and 13C-NMR data are given in Tables 2 and 3, respectively. 
 
Antiviral Activity Assays 
 
Antiviral activity against HSV-1, HSV-2, vaccinia virus, vesicular stomatitis virus, Coxsackie 
virus B4, respiratory syncytial virus, parainfluenza-3 virus, reovirus-1, Sindbis virus and Punta Toro 
virus was determined as described previously [13,14]. Antiviral activity was expressed as the EC50 or 
concentration required to reduce virus-induced cytopathogenicy by 50%. EC50 values were calculated 
from graphic plots of the percentage of cytopathogenicity as a function of concentration of the 
compounds. 
 
Antitumoral Activity Assays 
 
The HeLa (cervical carcinoma), MCF-7 (breast carcinoma), MiaPaCa-2 (pancreatic carcinoma), H 
460 (lung carcinoma), SW 620 (colon carcinoma) and WI 38 (diploid fibroblasts) cells were cultured 
as monolayers and maintained in Dulbecco's modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin 
in a humidified atmosphere with 5% CO2 at 37˚C. Antitumoral activity against L1210 (murine 
leukemia), Molt4/C8 and CEM (human T-lymphocytes) cell lines was measured essentially as 
originally described for the mouse leukemia (L1210) cell line [15]. 
The growth-inhibitory activity of HeLa, MCF-7, MiaPaCa-2, H 460, SW 620 and WI 38 cells was 
assessed according to a slightly modified procedure performed at the National Cancer Institute, 
Developmental Therapeutics Program [16]. The cells were seeded into a series of standard 96-well 
microtiter plates on day 0. Test agents were then added in five, 10-fold dilutions (10-8 to 10-4 M) and 
incubated for a further 72 hours. Working dilutions were freshly prepared on the day of testing. The 
solvent (DMSO) was also tested for eventual inhibitory activity by adjusting its concentration to be the 
same as for the tested concentrations. After 72 hours of incubation the cell growth rate was evaluated 
by MTT assay [17] which detects dehydrogenase activity in viable cells. The absorbance (OD, optical 
density) was measured by a microplate reader at 570 nm. The percentage of growth (PG) of the cell 
lines was calculated according to one or the other of the following two expressions: 
If (mean ODtest – mean ODtzero) ≥ 0, then: 
PG = 100 x (mean ODtest – mean ODtzero) / (mean ODctrl – meanODtzero) 
If (mean ODtest – mean ODtzero) < 0, then: 
G = 100 x (mean ODtest – mean ODtzero) / ODtzero 
where mean ODtzero = the average of optical density measurements before exposure of cells to the test 
compound, mean ODtest = the average of optical density measurements after the desired period of time 
and mean ODctrl = the average of optical density measurements after the desired period of time with no 
exposure of cells to the test compound. 
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Each test point was measured in quadruplicate in three individual experiments. The results are 
expressed as IC50, a concentration necessary for 50% of inhibition. Each result is a mean value from 
three separate experiments. The IC50 values for each compound were calculated from dose-response 
curves using linear regression analysis by fitting the test concentrations that gave PG values above and 
below the reference value (i.e. 50%). 
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